GlassScriptPhysician profile
Shervin Eshraghi
NPI 1538191507
$51,855.74
in general payments reported to CMS, 2019-2025
60 companies · $1,919 in 2025
The $1,919 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $4,164 · 2021: $10K · 2022: $3,285 · 2023: $2,816 · 2024: $1,115 · 2025: $1,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,170 · Consulting Fee: $300 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,169.94 |
| Consulting Fee | $300.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Education | $180.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $7,817.39 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $7,118.21 | 2019-2023 | Oxtellar Xr |
| Mdd US Operations, LLC | $6,206.61 | 2019-2023 | Apokyn |
| Lundbeck LLC | $4,549.07 | 2019-2021 | |
| Sk Life Science, INC. | $4,340.18 | 2020-2025 | Xcopri |
| Novartis Pharmaceuticals Corporation | $3,932.60 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $1,854.06 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Livanova USA, INC. | $1,515.88 | 2019-2021 | |
| Sarepta Therapeutics, INC. | $1,500.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $1,295.14 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $1,115.24 | 2019-2025 | Tysabri |
| Abbvie INC. | $969.60 | 2021-2025 | |
| Amgen INC. | $744.33 | 2019-2025 | Uplizna |
| Emd Serono, INC. | $695.82 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $631.31 | 2019-2023 | Ingrezza, Ongentys |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shervin Eshraghi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.